Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00634842 · ClinicalTrials.gov registry record · Phase 4
Effect of Two Different Fasting Blood Glucose Targets on Glucose Control in Patients With Type 2 Diabetes Using Insulin Detemir Once Daily
A Phase 4 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 4
- Development phase
- 244
- Enrollment target
NCT00634842: Completed Phase 4 study, sponsored by Novo Nordisk A/S.
NCT00634842 is a Phase 4 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 244 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (53% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00634842, a Phase 4 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 244 participants
- Enrollment target
Study Summary
This trial is conducted in the United States of America. The aim of this trial is to explore how different fasting blood glucose targets affect glucose control in patients with type 2 diabetes, when patients are empowered to do dose adjustments themselves.
Primary Outcome
Percentage (%) of subjects reaching glycosylated haemoglobin A1c (HbA1c) less than 7% measured after 20 weeks of treatment
Interventions
- DRUG insulin detemir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 244 participants |
| Start Date | 2008-02 |
| Est. Completion | 2008-10 |
| Phase | Phase 4 |
What the finished NCT00634842 record still lists
NCT00634842 is an interventional study that assigns participants to a tested intervention. The registered 244 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (53% lower).
The record links to 0 conditions, and to 1 intervention - of which insulin detemir is the first listed.
NCT00634842 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00634842 about?
NCT00634842 is a clinical study titled "Effect of Two Different Fasting Blood Glucose Targets on Glucose Control in Patients With Type 2 Diabetes Using Insulin Detemir Once Daily". This trial is conducted in the United States of America. The aim of this trial is to explore how different fasting blood glucose targets affect glucose control in patients with type 2 diabetes, when patients are empowered to do dose adjustments themselves.
What is the current status of trial NCT00634842?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 244 participants. The study started on 2008-02. Estimated completion is 2008-10.
What interventions are being tested in trial NCT00634842?
The interventions under investigation include: insulin detemir (DRUG).
Who is sponsoring clinical trial NCT00634842?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00634842's enrollment target sits among peer trials
244 357th of 2000 higher than 1,643 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02227251 · 244 participants · Phase 2
Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
- NCT04317534 · 244 participants · Phase 2
Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm
- NCT04683250 · 244 participants · Phase 1
Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities
- NCT04686305 · 244 participants · Phase 1
Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia